Medpace/$MEDP
13:30
09:10
04:45
00:25
20:00
1D1W1MYTD1Y5YMAX
About Medpace
Medpace is a late-stage contract research organization that provides full-service drug-development and clinical trial services to small and midsize biotechnology, pharmaceutical, and medical-device firms. It also offers ancillary services such as bioanalytical laboratory services and imaging capabilities. The company was founded over 30 years ago and has over 5,400 employees across 40 countries. Medpace is headquartered in Cincinnati and its operations are principally based in the US, but it also operates in Europe, Asia, South America, Africa, and Australia. Cinven, a global private equity firm, acquired Medpace for $915 million in 2014 and exited its investment in 2018.
Ticker
$MEDP
Sector
Primary listing
Industry
Life Sciences Tools & Services
Headquarters
Employees
5,900
ISIN
US58506Q1094
Website
Medpace Metrics
BasicAdvanced
$8.8B
23.44
$13.09
1.46
-
Price and volume
Market cap
$8.8B
Beta
1.46
52-week high
$459.77
52-week low
$250.05
Average daily volume
378K
Financial strength
Current ratio
0.732
Quick ratio
0.659
Long term debt to equity
21.337
Total debt to equity
25.328
Profitability
EBITDA (TTM)
485.513
Gross margin (TTM)
68.08%
Net profit margin (TTM)
19.31%
Operating margin (TTM)
21.16%
Effective tax rate (TTM)
13.49%
Revenue per employee (TTM)
$370,000
Management effectiveness
Return on assets (TTM)
15.44%
Return on equity (TTM)
65.82%
Valuation
Price to earnings (TTM)
23.438
Price to revenue (TTM)
4.388
Price to book
15.38
Price to tangible book (TTM)
-88.73
Price to free cash flow (TTM)
17.493
Free cash flow yield (TTM)
5.72%
Free cash flow per share (TTM)
1,753.81%
Growth
Revenue change (TTM)
9.87%
Earnings per share change (TTM)
33.36%
3-year revenue growth (CAGR)
21.13%
3-year earnings per share growth (CAGR)
34.77%
What the Analysts think about Medpace
Analyst ratings (Buy, Hold, Sell) for Medpace stock.
Bulls say / Bears say
Medpace reported Q1 2025 earnings of $3.67 per share, surpassing analyst expectations of $3.06, indicating strong financial performance. (Benzinga)
The company achieved a 9.3% year-over-year revenue increase in Q1 2025, reaching $558.57 million, showcasing robust growth. (TradingView News)
Medpace's backlog stood at approximately $2.85 billion at the end of Q1 2025, reflecting a strong pipeline of future projects. (Benzinga)
New business awards in Q1 2025 totaled $500 million, an 18.8% decline year-over-year, suggesting potential challenges in securing new contracts. (Benzinga)
Leerink Partners initiated coverage with a 'Market Perform' rating, citing concerns over elevated cancellation rates and a slowdown in new clinical trial starts due to reduced biotech funding post-COVID. (Nasdaq)
Medpace's stock has declined approximately 10.8% year-to-date as of April 2025, underperforming the S&P 500's decline of 10.2%, indicating potential investor concerns. (Finviz)
Data summarised monthly by Lightyear AI. Last updated on 8 Jun 2025.
Medpace Financial Performance
Revenues and expenses
Medpace Earnings Performance
Company profitability
Medpace News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Medpace stock?
Medpace (MEDP) has a market cap of $8.8B as of June 27, 2025.
What is the P/E ratio for Medpace stock?
The price to earnings (P/E) ratio for Medpace (MEDP) stock is 23.44 as of June 27, 2025.
Does Medpace stock pay dividends?
No, Medpace (MEDP) stock does not pay dividends to its shareholders as of June 27, 2025.
When is the next Medpace dividend payment date?
Medpace (MEDP) stock does not pay dividends to its shareholders.
What is the beta indicator for Medpace?
Medpace (MEDP) has a beta rating of 1.46. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.